- Home
- TCRX vs NKTX Comparison
TCRX vs NKTX Comparison
Compare TCRX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- NKTX
- Stock Information
- Founded
- TCRX 2018
- NKTX 2015
- Country
- TCRX United States
- NKTX United States
- Employees
- TCRX N/A
- NKTX 157
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- NKTX Health Care
- Exchange
- TCRX Nasdaq
- NKTX Nasdaq
- Market Cap
- TCRX 140.7M
- NKTX 147.7M
- IPO Year
- TCRX 2021
- NKTX 2020
- Fundamental
- Price
- TCRX $1.89
- NKTX $2.17
- Analyst Decision
- TCRX Strong Buy
- NKTX Strong Buy
- Analyst Count
- TCRX 5
- NKTX 5
- Target Price
- TCRX $9.40
- NKTX $13.50
- AVG Volume (30 Days)
- TCRX 656.4K
- NKTX 1.4M
- Earning Date
- TCRX 11-07-2025
- NKTX 11-07-2025
- Dividend Yield
- TCRX N/A
- NKTX N/A
- EPS Growth
- TCRX N/A
- NKTX N/A
- EPS
- TCRX N/A
- NKTX N/A
- Revenue
- TCRX $6,961,000.00
- NKTX N/A
- Revenue This Year
- TCRX $255.18
- NKTX N/A
- Revenue Next Year
- TCRX N/A
- NKTX N/A
- P/E Ratio
- TCRX N/A
- NKTX N/A
- Revenue Growth
- TCRX N/A
- NKTX N/A
- 52 Week Low
- TCRX $1.02
- NKTX $1.31
- 52 Week High
- TCRX $6.23
- NKTX $3.81
- Technical
- Relative Strength Index (RSI)
- TCRX 39.56
- NKTX 45.44
- Support Level
- TCRX $1.74
- NKTX $2.04
- Resistance Level
- TCRX $2.43
- NKTX $2.47
- Average True Range (ATR)
- TCRX 0.18
- NKTX 0.18
- MACD
- TCRX -0.07
- NKTX -0.04
- Stochastic Oscillator
- TCRX 14.46
- NKTX 11.35
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.